

Association of Platelet-Activating Factor Acetylhydrolase with Ankle-Brachial Index in Patients with Type 2 Diabetes Mellitus

Nearmeen M. Rashad^{1*}, Ayman E. Ali¹

¹Internal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

* Corresponding Author: Nearmeen M. Rashad¹

Tel.: +2 01224248642

E-mail address: nrashad78[at]yahoo.com

Abstract: *Background: Peripheral arterial disease (PAD) is a common cardiovascular complication in patients with type 2 diabetes mellitus (T2DM). Platelet-activating factor acetylhydrolase (PAF-AH) is a biomarker of vascular inflammation. The purpose of this study was to evaluate the influence of T2DM on PAF-AH activity in patients with or without PAD. Methods: cross sectional case control study included 180 subjects were stratified into control and T2DM group, the enzymatic activity of (PAF-AH) was determined by a colorimetric assay. Results: there were significant higher values of serum PAF-AH in patients with T2DM with moderate and severe PAD compared to patients with mild PAD. Regarding ankle-brachial index (ABI) there was highly significant lower values in moderate and severe diabetic patient with PAD compared to patients with mild PAD. By linear regression analysis test body mass index, HDL, LDL and fasting plasma glucose were independently correlated with PAF-AH. Receiver operating characteristic analyses (ROC) revealed that the sensitivity and specificity power of PAF-AH among T2DM patients were (97.5%, 60% respectively). Conclusion: plasma PAF-AH levels are significant high in T2DM patients as well as patients with severe PAD and strongly correlated with ABI as well as other lipid and metabolic disorders.*

Keywords: Peripheral arterial disease, PAF-AH, ABI

1. Introduction

Type 2 diabetes mellitus is a risk factor for atherosclerosis which is responsible for coronary heart disease, peripheral arterial disease, and cerebrovascular disease [1]. In Egypt, the prevalence of diabetes is around 15.5% among adults' population, with an annual death of 86, 478 related to diabetes [2].

Peripheral artery disease (PAD) is associated with an increased risk of cardiovascular morbidity and mortality [3, 4], clinical manifestation of PAD, including functional decline, intermittent claudication, critical leg ischemia, and amputation, [5]. Patients with diabetes mellitus often have extensive and severe PAD and a greater propensity for arterial calcification [6].

platelet-activating factor acetylhydrolase) is a member of the intracellular and secretory phospholipase enzyme family secreted by activated macrophages [7, 8]. The plasmatic PAF-AH is constitutively active and circulates bound to LDL, HDL and other lipoproteins and catalyses the hydrolysis of the sn2 acetate of PAF and PAF mimetics, which are early mediators of inflammation [9]. PAF activates a variety of cells of the innate immune system promoting migration, adhesion and inflammatory effects. Thus, PAF-AH while inactivating PAF is considered an important factor in preventing an exaggerated inflammatory response and in protecting cells from uncontrolled oxidative damage [10]. The ankle-brachial index is a useful tool for specific, cost-effective, noninvasive diagnosis for peripheral artery disease. [11, 12] a low ABI (≤ 0.9) is strongly associated with generalized atherosclerosis, cardiovascular mortality and all-cause death, regardless of the presence of symptoms. [13, 14]. In diabetic patients, the risk of

peripheral vascular disease (PVD) is increased and occurs earlier and diffuse as well as more severe. ABI is still a relevant method because it is non-invasive as well as cheap; therefore the aim of our research was to estimate PAF-AH plasmatic activity and to clarify the possible correlation between PAF-AH and ABI, which reflect PAD as well as other clinical-laboratory features of type 2 diabetes.

2. Subjects and Methods

A cross-sectional case control study included 180 unrelated subjects. One hundred thirty patients with type 2 diabetes mellitus recruited from Diabetes and Endocrinology outpatient clinic of Internal Medicine Department of Zagazig University Hospitals and 50 healthy controls, who were matched to cases by age and ethnic origin. Diabetic patients were stratified into three subgroups according to ABI. All patients were subjected to thorough history taking and full clinical assessment including blood pressure, patients with history of respiratory disease, cancer, severe hepatic, renal diseases, acute illness, hormonal therapy, any active inflammatory diseases were excluded from the study. The ethical committee of Faculty of Medicine, Zagazig University approved our study protocol, and all participants assigned written informed consent. ABI is an easy way to compare the systolic pressure of the upper extremity with that of the affected lower extremity. The systolic pressure in the pedal arteries (dorsalis pedis or posterior tibial) was measured using a handheld 5-MHz. Doppler probe and a blood pressure cuff. The higher of these two measurements was compared with a similarly taken brachial artery systolic pressure. A ratio ankle/brachial of 0.9 or less is considered a sign of impaired flow to the extremity [15, 16]. Patients were classified according to ABI into three categories: I <

0.9-0.7 (mild PAD), II< 0.7-0.5 (moderate PAD) and III < 0.5-0.3 (severe PAD).

Blood sampling: Blood samples were drawn from all subjects after an overnight fast. We measured fasting blood glucose using the glucose oxidase method (Spinreact, Girona, Spain). Total cholesterol, HDL cholesterol, and triglycerides were measured by routine enzymatic methods (Spinreact, Girona, Spain). LDL cholesterol was calculated using the Friedewald formula [17]. PAF-AH activity was analyzed using the colorimetric method with a commercial kit according to instructions provided by the manufacturer (Cayman Chemical Statistical analysis).

Data analyses were done with statistical package for the social sciences software (SPSS Version 21, Chicago, Illinois). Data were expressed as mean ± standard deviation (SD). The relationships of PAF-AH levels with clinical and laboratory parameters among T2DM patients were tested with the Pearson rank correlation. Receiver operating characteristic (ROC) analysis was performed to assess the potential accuracy of serum PAF-AH for diagnosis of PAD. A linear regression analysis was done to detect the main predictors of PAF-AH levels in T2DM patients. We considered P to be significant at <0.05 with a 95% confidence interval (CI).

Clinical and Biochemical Characteristics of the Studied Groups

In T2DM group, we found significant higher values of BMI, waist/hip ratio, FMI, systolic, diastolic pressure, TG, LDL, FPG and HbA1c compared to controls. On the contrary, we detected significant lower HDL cholesterol in T2DM patients than in those healthy subjects. (Table 1).

Table 1: Clinical, anthropometric and laboratory characteristics of all studied subjects

	Control group (n=50)	T2DM group (n=130)	P
Age (years)	45.8±11.14	44.4±10.35	0.07
Systolic pressure	127.14±6.0	136.5±14.1	<0.001*
Diastolic pressure	83.58±4.75	88.66±7.1	<0.001*
Waist /hip ratio	0.939±0.07	0.97±0.05	<0.001*
BMI	23.26±0.96	26.5±6.189	<0.001*
FMI (kg/m2)	4.65±0.192	7.3±1.139	<0.001*
TC (mg/dL)	168.88±9.9	176.7±29.7	0.06
TG (mg/dL)	135.8±13.3	178.3±37.2	<0.001*
LDL.C (mg/dL)	87.1±10.63	107.5±32.1	<0.001*
HDL.C (mg/dL)	50.9±5.53	48.81±6.41	<0.001*
FPG (mg/dL)	86.8±5.08	180.1±24.9	<0.001*
HbA1c (%)	5.33±0.382	7.37±0.53	<0.001*

Clinical and Biochemical Characteristics of Diabetic Groups

We classified T2DM groups according to severity of PAD to three subgroups. In group III, we found significant higher values of BMI, FMI, LDL, FPG and TC compared to group I. On the contrary, we detected significant lower HDL in group III patients than group I. Regarding group II, we observed significant higher values of BMI, LDL and TC compared to group I, (Table 2).

Table 2: Laboratory and anthropometric parameters in Type 2 DM group stratified according to ABI.

	Group I (n=69)	Group II (n=35)	Group III (n=26)
Age (years)	44.43±10.3	42.66±10.0	42.24±9.66
Waist /hip ratio	0.95±0.067	0.98±0.052	1.03±0.05
BMI	23.9±5.16*	24.6±4.81 [§]	28.56±6.47
FMI (kg/m2)	6.64±1.186	7.55±0.86 [§]	7.68±1.041
Systolic pressure	133.7±12.6	137.4±13.2	137.6±14.9
Diastolic pressure	87.58±5.83	89.05±7.79	89.12±6.32
TC (mg/dL)	168.3±11.1*	185.5±38.5 [§]	187.2±42.3
TG (mg/dL)	178.1±11.2	169.8±47.9	190.8±58.8
LDL.C (mg/dL)	83.65±20.9*	128.5±18.2 [§]	143.1±14.4
HDL.C (mg/dL)	49.7±4.8*	49.03±7.28 [§]	45.96±8.11
FPG (mg/dL)	174.4±26.2*	184.2±21.1 [§]	190.2±22.1
HbA1c (%)	7.25±1.31	7.34±1.36	7.45±1.64

Comparison of PAF-AH (nmol/min/ml) and ABI values among the studied groups

Moderate and severe diabetic patient with PAD had significantly higher values of serum PAF-AH (24.21±2.78 and 31.44±4.08, respectively) compared to mid PAD group (21.68±3.36) (Fig.1). On the contrary, there was highly significant lower values of ABI in moderate and severe diabetic patient with PAD (0.57±0.062 and 0.43±0.056, respectively) compared to mid PAD group (0.87±0.049) (Fig.2).




Figure 1: Comparison of PAF-AH (nmol/min/ml) levels among the studied groups




Figure 2: Comparison of ABI levels among the studied groups

Correlation between PAF-AH, ABI, and other parameters among T2DM groups

In T2DM group, PAF-AH levels were significantly positive correlated with waist /hip ratio, BMI, triglycerides, LDL and FPG, On the contrary, PAF-AH levels were significantly negative correlated with HDL (P<0.05). Regarding ABI, there were significantly positive correlated with HDL, On the contrary, ABI levels were significantly negative

correlated with BMI, TC, LDL, HDL, FPG, HbA1c and FMI (Table 3).

Table 3: Pearson correlations between ABI, PAF-AH (nmol/min/ml) and other parameters of studied groups

Variable	ABI		PAF-AH	
	r	p	r	p
Age (year)	-0.150	0.088	0.131	0.139
Systolic pressure	-0.063	0.475	0.153	0.083
Diastolic pressure	-0.060	0.498	0.033	0.706
FMI (kg/m ²)	-0.261	<0.001*	0.020	0.819
Waist /hip ratio	-0.003	0.192	0.217	<0.01*
BMI	-0.380	<0.001*	0.190	<0.01*
TC (mg/dL)	-0.287	<0.001*	0.114	0.195
TG (mg/dL)	-0.035	0.693	0.205	<0.05
LDL.C (mg/dL)	-0.759	<0.001*	0.476	<0.001*
HDL.C (mg/dL)	0.202	<0.01*	-0.281	<0.001*
FPG (mg/dL)	-0.186	<0.01*	0.525	<0.001*
HbA1c	-0.218	<0.01*	0.055	0.531

Correlation between PAF-AH (nmol/min/ml) and ABI among T2DM groups

In T2DM group, PAF-AH levels were significantly negative correlated with ABI (r=0.529, p<0.001) as demonstrated in figure3.




Figure 3: Pearson correlation between PAF-AH (nmol/min/ml) and ABI in studied groups

Linear regression analysis in T2DM groups

In T2DM group, linear regression analysis revealed that BMI, HDL, LDL and FPG were the main predictors of PAF-AH levels among other clinical and laboratory biomarkers (Table 4).

Table 4: linear regression analyses in elderly patients to test the influence of the main independent variables against PAF-AH (mm) (dependent variable)

Model	Unstandardized Coefficients		Standardized Coefficients	t	p	95% C.I.	
	B	SE	Beta			Lower Bound	Upper Bound
Constant	1.669	7.634		0.219	0.827	16.78	13.447
BMI	0.189	0.062	0.235	3.025	<0.001*	0.312	0.065
FPG	0.069	0.013	0.346	5.105	<0.001*	0.042	0.096
LDL.C	0.056	0.010	0.363	5.506	<0.001*	0.036	0.076
HDL.C	-0.144	0.056	-0.186	-2.559	<0.001*	-2.256	-0.033
TG	0.019	0.009	0.139	2.071	<0.05*	0.001	0.036
Waist /hip ratio	14.791	5.531	0.177	2.674	<0.001*	3.839	25.742

Accuracy of circulating PAF-AH levels for assessment of PAD severity by ROC analysis

The power of PAF-AH levels to assess the severity of PAD among T2DM studied subjects was evaluated using ROC analysis. When we compared our patients (n=130) with healthy subjects (n=50), the AUC was 0.981 (95% CI = 0.899-0.986) with sensitivity = 88.3%, specificity = 70%, and the cutoff values (19.16) (Fig. 4). In attempt to differentiate between mild and moderate PAD, the cutoff values were (17.4375) and the AUC was 0.954 (95% CI = 0.901-0.988). Additionally, the sensitivity and the specificity were (97.5%, 60% respectively). (Fig. 5). Regarding sever PAD, the AUC was 0.899 (95% CI = 0.839-0.958) with sensitivity = 91.4%, specificity = 60%, and the cutoff values (24.22). (Fig. 6).




Figure 4




Figure 5




Figure 6

3. Discussion

Peripheral arterial disease (PAD) is a public health problem across the world with a significant impact on healthcare and a high economic burden [18-22]. It is associated with an increased risk of cardiovascular disease [23-25], and is particularly common in patients with type 2 diabetes [26-29]. PAD affects 9% - 23% of people over 55 years of age [30, 31] among them, only 10% reveal the typical symptoms of intermittent claudication, whereas 50% have other leg symptoms and the remaining 40% are asymptomatic [22, 23].

The main cause of death in patients with PAD is associated with CV and/or cerebrovascular events, rather than complications related to PAD itself, as PAD is mostly a powerful indicator of progressive, systemic atherosclerotic disease, the results of limited studies regarding the influence of PAF-AH plasmatic activity on PAD are unclear, thus the purpose of our study was to evaluate the influence of type 2 diabetes and cardio metabolic markers on PAF-AH activity in patients with or without PAD.

Our results revealed that, there were significant higher values of BMI, waist/hip ratio, FMI, systolic blood, diastolic blood pressure, triglycerides, LDL, FPG and HbA1c in T2DM groups compared to controls group. Moreover, there were significant higher values of BMI, FMI, LDL, TC and FPG. In patients with severe PAD compared to patients with mild PAD.

In agreement with our results Aboleineen et al. [33] study found that, there was significant difference between the groups regarding TC and TG being higher among group. The same results were perceived in a study of Liang et al. [34]

The main finding of our research that, there were significant higher values of serum PAF-AH in diabetic patients with moderate and sever PAD compared patients with mild PAD. Regarding ABI there was highly significant lower values in moderate and sever diabetic patient with PAD compared to patients with mild PAD.

The finding of our present study consistent with our previous researches [35, 36] which demonstrated that diabetic patients, cardiovascular risk patients, and the general patient population with borderline ABI had a poorer prognosis than those with normal ABI [35, 36]. The same results were conducted by a study of Natsuaki et al. [37] and Tanaka et al. [38]. Also Serban et al noticed that the PAF-AH levels were significantly higher in patients with both NIDDM and dyslipidemia, as compared to healthy subjects.

Concordance with our finding, Aboleineen et al. found that, there was difference between diabetic and non-diabetic patients regarding the distribution of arterial tree affection in the lower limbs; diabetic patients had more severe arterial affection in the below knee arteries (popliteal, anterior tibial, peroneal, posterior tibial) than non-diabetic patients [33].

Similar to our findings Jude et al observed greater severity of arterial disease in diabetic patients in the all arterial segments below the knee [39].

These results were supported previously by de Castro et al who studied on type 1 DM and they found that higher enzyme activity of PAF-AH in patients with DM 1 than in control subjects [40], It seems probable that hyperglycemia causes endothelial dysfunction, vascular inflammation, arterial wall hypertrophy and fibrosis, which are all interrelated processes that lead to vascular damage with arterial stiffness [41, 42].

Several lines of evidence provide information about the relationships of Lp-PLA2 biomarkers with coronary heart disease and ischemic stroke. To our knowledge, no previous studies reported associations of PAF-AH activity as a member of Lp-PLA2 family with PAD in diabetic as well as non-diabetic subjects. Our study found that, there was positive correlation between PAF-AH levels with waist /hip ratio, BMI, triglycerides, LDL and FPG.

Meanwhile, according to our results ABI levels were significantly negative correlated with BMI, total cholesterol, LDL, HDL, FPG, HbA1c and FMI. For further evaluation of the main effectors of PAF-AH among T2DM group, linear regression analysis test was done. Our results showed that, BMI, HDL, LDL and fasting plasma glucose were independently correlated with PAF-AH.

These results agree with those reported in Garg et al. they detected that higher Lp-PLA2 mass and activity were associated with development of both incident clinical PAD and low ABI [45].

In line with the current knowledge of Serban et al found positive correlation between PAF-AH activity and LDL-ch/HDL-ch ratio in patients with NIDDM [46].

Similar results obtained by de Castro et al they observed that, in patients with DM 1, a direct correlation between PAF-AH activity and LDL, and an inverse correlation between PAF-AH and high-density lipoprotein (HDL) were found [42].

In line with the current knowledge of Serban et al found positive correlation between PAF-AH activity and LDL-ch/HDL-ch ratio in patients with NIDDM [44].

Similar results obtained by de Castro et al they observed that, in patients with DM 1, a direct correlation between PAF-AH activity and LDL, and an inverse correlation between PAF-AH and high-density lipoprotein (HDL) were found [40].

We analyzed our data by ROC to estimate the cut off, sensitivity and specificity of PAF-AH in differentiating between different degrees of PAD. The sensitivity and specificity were (97.5%, 60% respectively). Thus PAF-AH could be useful diagnostic test discriminate different degrees of PAD especially moderate PAD from mild PAD.

In conclusion, plasma PAF-AH levels are high in T2DM patients as well as patients with severe PAD compared to mild group. PAF-AH levels are correlated with ABI as well as other lipid and metabolic disorders thus plasma PAF-AH could be used as marker of vascular inflammation and atherosclerosis. We recommend further studies on a population to support these findings.

Acknowledgments: the authors thank doctors of clinical pathology department, faculty of medicine, Zagzig University for their efforts and help in this research.

References

- [1] Held, C., Hjerdahl, P., Eriksson, S.V., Björkander, I. Forslund, L. and Rehnqvist, N. Prognostic implications of intima media thickness and plaques in the carotid and femoral arteries in patients with stable angina pectoris. *European Heart Journal* 2001; 22, 62-72.
- [2] International Diabetes Federation. The IDF Diabetes Atlas Seventh Edition, (2015). Available from <http://www.idf.org/diabetesatlas>.
- [3] Allison MA, Ho E, Denenberg JO, et al. Ethnic-specific prevalence of peripheral artery disease in the United States. *Am J Prev Med* 2007; 32:328–33.
- [4] Hirsch AT, Haskal ZJ, Hertzner NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral artery disease (lower extremity, renal, mesenteric, and abdominal aortic) : a collaborative report from the American Association for VascularSurgery/Society for Vascular Surgery, Society for Cardiovascular Angiographyand Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHATask Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Artery Disease). *J Am Coll Cardiol* 2006;47: e1–192.
- [5] Herman SD, Liu K, Tian L, et al. Baseline lower extremity strength and subsequent decline in functional performance at 6-year follow-up in persons with lower extremity peripheral artery disease. *J Am Geriatr Soc* 2009; 57:2246–52
- [6] Aboyans V, Criqui MH, Denenberg JO, et al: Risk factors for progression of peripheral arterial disease in large and small vessels. *Circulation* 113:2623, 2006.
- [7] Lerman A., McConnell J.P. Lipoprotein-associated phospholipase A2: A risk marker or a risk factor? *Am. J. Cardiol.* 2008; 101:11F–22F.
- [8] Vittos O., Toana B., Vittos A., Moldoveanu E. Lipoprotein-associated phospholipase A2 (Lp-PLA2) : A review of its role and significance as a cardiovascular biomarker. *Biomarkers.* 2012; 17:289–302.
- [9] McIntyre TM, Prescott SM, Stafforini DM. The emerging roles of PAF acetylhydrolase. *J Lipid Res.* 2009;50 (Suppl) : S255–S259.
- [10] Rosenson RS, Stafforini DM. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. *J Lipid Res.* 2012;53 (9) :1767–1782. doi: 10.1194/jlr.R024190.
- [11] Alahdab F, Wang AT, Elraiayah TA, Malgor RD, Rizvi AZ, Lane MA, et al. A systematic review for the screening for peripheral arterial disease in asymptomatic patients. *J Vasc Surg.* 2015; 61: 42S–53S.
- [12] Rac-Albu M, Iliuta L, Guberna SM, Sinescu C. The role of ankle-brachial index for predicting peripheral arterial disease. *Maedica (Buchar).* 2014; 9 (3) :295–302.
- [13] Kojima I, Ninomiya T, Hata J, Fukuhara M, Hirakawa Y, et al. A low ankle brachial index is associated with an increased risk of cardiovascular disease: The Hisayama study. *J Atheroscler Thromb.* 2014;21 (9) :966–73.]
- [14] Suominen V, Uurto I, Saarinen J, Venermo M, Salenius J. PAD as a risk factor for mortality among patients with elevated ABI—a clinical study. *Eur J Vasc Endovasc Surg.* 2010. March;39 (3) :316–22.
- [15] Grenon SM, Gagnon J, Hsiang Y. Video in clinical medicine. Ankle-brachial index for assessment of peripheral arterial disease. *N Engl J Med* 2009; 361: e40.
- [16] Lyden SP, Joseph D. The clinical presentation of peripheral arterial disease and guidance for early recognition. *Cleve Clin J Med* 2006; 73 (Suppl) : S15–S21.
- [17] Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 18:499–502.
- [18] Mahoney EM, Wang K, Keo HH, Duval S, Smolderen KG, et al.. Reduction of atherothrombosis for continued health (REACH) registry investigators—vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. *Circ Cardiovasc Qual Outcomes.* 2010;3 (6) :642–651. doi: 10.1161/CIRCOUTCOMES.109.930735
- [19] Malyar N, Furstenberg T, Wellmann J, Meyborg M, Luders F, et al.. Recent trends in morbidity and in-hospital outcomes of in-patients with peripheral arterial disease: a nationwide population-based analysis. *Eur Heart J.* 2013;34 (34I) :2706–2714.
- [20] Hirsch AT, Duval S. The global pandemic of peripheral artery disease. *Lancet.* 2013;382 (9901I) :1312–1314.
- [21] Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. *Lancet.* 2013;382 (9901I) :1329–1340. doi: 10.1016/S0140-6736 (13) 61249-0.
- [22] Marrett E, DiBonaventura M, Zhang Q. Burden of peripheral arterial disease in Europe and the United States: a patient survey. *Health Qual Life Outcomes.* 2013; 11:175.
- [23] Jones WS, Patel MR, Rockman CB, Guo Y, Adelman M, et al. Association of the ankle-brachial index with history of myocardial infarction and stroke. *Am Heart J.* 2014;167 (4I) :499–505.
- [24] Emdin CA, Anderson SG, Callender T, Conrad N, Salimi-Khorshidi G, et al. Usual blood pressure, peripheral arterial disease, and vascular risk: cohort study of 4.2 million adults. *BMJ.* 2015; 351:4865
- [25] Lin YS, Tung TH, Wang J, Chen YF, Chen TH, et al. Peripheral arterial disease and atrial fibrillation and risk of stroke, heart failure hospitalization and cardiovascular death: a nationwide cohort study. *Int J Cardiol.* 2016; 203:204–211.

- [26] Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. *DiabetesCare*. 2001;24 (8I) :1433–1437.
- [27] Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. *Circulation*. 2004;110 (6I) :738–743.
- [28] Joosten MM, Pai JK, Bertola ML, Rimm EB, Spiegelman D, et al. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. *JAMA*. 2012;308 (16I) :1660–1667
- [29] Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. *Lancet Diabetes Endocrinol*. 2015;3 (2) :105–113.
- [30] Hirsch AT, Duval S. The global pandemic of peripheral artery disease. *Lancet*. 2013;382 (9901I) :1312–1314.
- [31] Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. *Lancet*. 2013;382 (9901I) :1329–1340.
- [32] Vittos O., Toana B., Vittos A., Moldoveanu E. Lipoprotein-associated phospholipase A2 (Lp-PLA2) : A review of its role and significance as a cardiovascular biomarker. *Biomarkers*. 2012; 17:289–302.
- [33] Mohamed Wafaie Aboleineen, Ragab Abdelsalam Mahfouz, Tamer Mohamed Moustafa, Mohamed Safwat Abdeldayem* pattern of peripheral arterial disease in diabetic and non-diabetic patients: association and risks correlation z.u.m.j.vol. 20; n.3; may; 2014.
- [34] Liang Y, Yan z, Sun B, etc. Cardiovascular Risk Factor Profiles for Peripheral Artery Disease and Carotid Atherosclerosis among Chinese Older People: A Population-Based Study *PLoS One*. 2014; 9 (1): e85927.
- [35] Kojima I, Ninomiya T, Hata J, Fukuhara M, Hirakawa Y, Mukai N, et al. A low ankle brachial index is associated with an increased risk of cardiovascular disease: the Hisayama study. *J Atheroscler Thromb*. 2014;21 (9) :966–73.
- [36] Murphy TP, Dhangana R, Pencina MJ, D'Agostino RB Sr. Ankle-brachial index and cardiovascular risk prediction: an analysis of 11, 594 individuals with 10-year follow-up. *Atherosclerosis*. 2012. January;220 (1) :160–7.
- [37] Natsuaki C, Inoguchi T, Maeda Y, Yamada T, Sasaki S, Sonoda N, et al. Association of borderline ankle-brachial index with mortality and the incidence of peripheral artery disease in diabetic patients. *Atherosclerosis*. 2014. June; 234 (2) :360–5
- [38] Tanaka S, Kaneko H, Kano H, Matsuno S, Suzuki S, Takai H, et al. The predictive value of the borderline ankle-brachial index for long-term clinical outcomes: An observational cohort study. *Atherosclerosis* 2016. July; 250:69–76.
- [39] Jude EB, Oyibo SO, Chalmers N, et al. Peripheral arterial disease in diabetic and non-diabetic patients: a comparison of severity and outcome. *Diabetes Care*. 2001 Aug;24 (8) :1433-7.
- [40] De Castro SH, Faria Neto HC, Gomes MB. Platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with type 1 diabetes mellitus. *Arq Bras Cardiol*. 2007 Feb;88 (2) :179-84.
- [41] Stehouwer C.D., Henry R.M., Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: A pathway to cardiovascular disease. *Diabetologia*. 2008; 51:527–539.
- [42] Christen A.I., Armentano R.L., Miranda A., Graf S., Santana D.B., Zócalo Y., Baglivo H.P., Sánchez R.A. Arterial wall structure and dynamics in type 2 diabetes mellitus methodological aspects and pathophysiological findings. *Curr. Diabetes Rev*. 2010; 6:367–377
- [43] Parveen K. Garg, Alice M. Arnold, Karen D. Hinckley Stukovsky, Carol Koro, Nancy S. Jenny, et al., Lipoprotein-Associated Phospholipase A2 and Incident Peripheral Arterial Disease in Older Adults. *The Cardiovascular Health Study Arterioscler Thromb Vasc Biol* April 2016.
- [44] M. Serban, Cristina Tanaseanu, T. Kosaka, Cristina Vidulescu Irina Stoian, Daciana S. Marta, et al. Significance of platelet-activating factor acetylhydrolase in patients with non-insulin-dependent (type 2) diabetes mellitus *J.Cell.Mol.Med*. Vol 6, No 4, 2002 pp. 643-647.
- [45] Christen A.I., Armentano R.L., Miranda A., Graf S., Santana D.B., et al., Arterial wall.

Author Profile



Prof. Dr/ Nearmeen M. Rashad Associate Professor of Internal medicine and Endocrinology. Faculty of Medicine, Zagazig University.



Dr/Ayman E. Ali, Lecturer of Internal medicine, Faculty of Medicine, Zagazig University.